Omega-3 fatty acids prevent the ketamine-induced increase in acetylcholinesterase activity in an animal model of schizophrenia

Life Sciences

Volumn 121, Issue , 2015, Pages 65-69

  Zugno, Alexandra I ^a,c   Chipindo, Helder ^a   Canever, Lara ^a   Budni, Josiane ^a   Alves De Castro, Adalberto ^a   Bittencourt De Oliveira, Mariana ^a   Heylmann, Alexandra Stephanie ^a   Gomes Wessler, Patrícia ^a   Da Rosa Silveira, Flávia ^a   Damázio, Louyse S ^a   Mastella, Gustavo Antunes ^a   Kist, Luiza W ^b,c   Bogo, Maurício R ^b,c   Quevedo, João ^a,c,d   Gama, Clarissa S ^a,c  

^a Universidade Do Extremo Sul   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Instituto Nacional de Ciência e Tecnologia Translacional em Medicina INCT TM   (Brazil)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Acetylcholinesterase; Ketamine; Omega 3 fatty acids; Schizophrenia

Indexed keywords

ACETYLCHOLINESTERASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; KETAMINE; OMEGA 3 FATTY ACID; AMINO ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC SYSTEM; CORPUS STRIATUM; ENZYME ACTIVITY; GENE EXPRESSION; HIPPOCAMPUS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOSTRIATUM; WISTAR RAT;

ANIMALIA; RATTUS NORVEGICUS;

ACETYLCHOLINESTERASE; ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; FATTY ACIDS, OMEGA-3; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HIPPOCAMPUS; KETAMINE; MALE; NEOSTRIATUM; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SCHIZOPHRENIA;

EID: 84919784802     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.11.025     Document Type: Article

References (46)

1. M.C. Aguilar, M. Gurpegui, F.J. Diaz, and J. De Leon Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions Br. J. Psychiatry 186 2005 215 221
2. G.P. Amminger, M.R. Schäfer, K. Papageorgiou, C.M. Klier, S.M. Cotton, S.M. Harrigan, A. Mackinnon, P.D. McGorry, and G.E. Berger Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial Arch. Gen. Psychiatry 67 2 2010 146 154 10.1001/archgenpsychiatry.2009.192
3. G.P. Amminger, M.R. Schäfer, C.M. Klier, J.M. Slavik, I. Holzer, M. Holub, S. Goldstone, T.J. Whitford, P.D. McGorry, and M. Berk Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals Mol. Psychiatry 17 12 2012 1150 1152 10.1038/mp.2011.167
4. J. Assies, R. Lieverse, P. Vreken, R.J. Wanders, P.M. Dingemans, and D.H. Linszen Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group Biol. Psychiatry 49 6 2001 510 522 10.1016/S0006-3223(00)00986-0
5. A. Barnes Race and hospital diagnoses of schizophrenia and mood disorders Soc. Work 53 1 2008 77 83
6. B.E. Bonefeld, B. Elfving, and G. Wegener Reference genes for normalization: a study of rat brain tissue Synapse 62 4 2008 302 309 10.1002/syn.20496
7. S. Brimijoin, and P. Hammond Transient expression of acetylcholinesterase messenger RNA and enzyme activity in developing rat thalamus studied by quantitative histochemistry and in situ hybridization Neuroscience 71 2 1996 555 565
8. T. Burt Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents Curr. Psychiatry Rep. 2 6 2000 473 478
9. D. Carretta, M. Santarelli, A. Sbriccoli, F. Pinto, C. Catini, and D. Minciacchi Spatial analysis reveals alterations of parvalbumin- and calbindin-positive local circuit neurons in the cerebral cortex of mutant mdx mice Brain Res. 1016 1 2004 1 11 10.1016/j.brainres.2004.04.021
10. S. Chalon Omega-3 fatty acids and monoamine neurotransmission Prostaglandins. Leukot. Essent. Fatty Acids 75 2006 259 269
11. M. Chatterjee, R. Verna, S. Ganguly, and G. Palit Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice Neuropharmacology 63 2012 1161 1171
12. L.A. Daiello, B.R. Ott, E.K. Festa, M. Friedman, L.A. Miller, and W.C. Heindel Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease J. Clin. Psychopharmacol. 30 3 2010 245 251 10.1097/JCP.0b013e3181da5406
13. S.C. Dyall, G.J. Michael, R. Whelpton, A.G. Scott, and A.T. Michael-Titus Dietary enrichment with omega-3 polyunsaturated fatty acids reverses age-related decreases in the GluR2 and NR2B glutamate receptor subunits in rat forebrain Neurobiol. Aging 28 3 2007 424 439 10.1016/j.neurobiolaging.2006.01.002
14. G.L. Ellman, K.D. Coutney, V. Andres Jr., and R.M. Feather-Stone A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88 95
15. W.W. Fleischhacker Problems in evaluating new antipsychotic drugs Wien. Med. Wochenschr. 148 11-12 1998 266 272
16. C.S. Gama, L. Canever, B. Panizzutti, C. Gubert, L. Stertz, R. Massuda, M. Pedrini, D.F. de Lucena, R.D. Luca, D.B. Fraga, A.S. Heylmann, P.F. Deroza, and A.I. Zugno Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia Schizophr. Res. 141 2-3 2012 162 167 10.1016/j.schres.2012.08.002
17. B. Grintal, G. Champeil-Potokar, M. Lavialle, S. Vancassel, S. Breton, and I. Denis Inhibition of astroglial glutamate transport by polyunsaturated fatty acids: evidence for a signalling role of docosahexaenoic acid Neurochem. Int. 54 8 2009 535 543 10.1016/j.neuint.2009.02.018
18. M. Haag, O.N. Magada, N. Claassen, L.H. Böhmer, and M.C. Kruger Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption Prostaglandins Leukot. Essent. Fat. Acids 68 6 2003 423 429 10.1016/S0952-3278(03)00067-X
19. K. Herholz, S. Weisenbach, E. Kalbe, N.J. Diederich, and W.D. Heiss Cerebral acetylcholine esterase activity in mild cognitive impairment Neuroreport 16 13 2005 1431 1434
20. R. Cachope, and J.F. Cheer Local control of striatal dopamine release Front. Behav. Neurosci. 8 2014 188 10.3389/fnbeh.2014.00188
21. D.F. Horrobin, A.I. Glen, and K. Vaddadi The membrane hypothesis of schizophrenia Schizophr. Res. 13 3 1994 195 207
22. D.F. Horrobin The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia Schizophr. Res. 30 3 1998 193 208
23. M.J. Hunt, B. Raynaud, and R. Garcia Ketamine dose-dependently induces high-frequency oscillations in the nucleus accumbens in freely moving rats Biol. Psychiatry 60 11 2006 1206 1214 10.1016/j.biopsych.2006.01.020
24. H.M. Ibrahim, and C.A. Tamminga Treating impaired cognition in schizophrenia Curr. Pharm. Biotechnol. 13 8 2012 1587 1594
25. T. Kaur, and K.S. Cadenhead Treatment implications of the schizophrenia prodrome Curr. Top. Behav. Neurosci. 4 2010 97 121
26. M.M. Khan, D.R. Evans, V. Gunna, R.E. Scheffer, V.V. Parikh, and S.P. Mahadik Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics Schizophr. Res. 58 1 2002 1 10
27. E.D. Levin α7-Nicotinic receptors and cognition Curr. Drug Targets 13 5 2012 602 606
28. R.L. Loewy, S. Therman, M. Manninen, M.O. Huttunen, and T.D. Cannon Prodromal psychosis screening in adolescent psychiatry clinics Early Interv. Psychiatry 6 1 2012 69 75 10.1111/j.1751-7893.2011.00286.x
29. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1 1951 265 275
30. K.M. Mackowick, M.S. Barr, V.C. Wing, R.A. Rabin, C. Ouellet-Plamondon, and T.P. George Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems Prog. Neuro-Psychopharmacol. Biol. Psychiatry S0278-5846 13 2013 151 156 10.1016/j.pnpbp.2013.07.010
31. J.R. Marszalek, and H.F. Lodish Docosahexaenoic acid, fatty acid-interacting proteins, and neuronal function: breastmilk and fish are good for you Annu. Rev. Cell Dev. Biol. 21 2005 633 657 10.1146/annurev.cellbio.21.122303.120624
32. J.D. Moreira, L. Knorr, A.P. Thomazi, F. Simão, C. Battú, J.P. Oses, C. Gottfried, S. Wofchuk, C. Salbego, D.O. Souza, M.L. Perry, and L. Vinadé Dietary omega-3 fatty acids attenuate cellular damage after a hippocampal ischemic insult in adult rats J. Nutr. Biochem. 21 4 2010 351 356 10.1016/j.jnutbio.2009.01.013
33. M. Peet Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia Isr. J. Psychiatry Relat. Sci. 45 1 2008 19 25
34. D. Piomelli, C. Pilon, B. Giros, P. Sokoloff, M.P. Martres, and J.C. Schwartz Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism Nature 353 6340 1991 164 167
35. P. Powchik, M. Davidson, V. Haroutunian, S.M. Gabriel, D.P. Purohit, D.P. Perl, P.D. Harvey, and K.L. Davis Postmortem studies in schizophrenia Schizophr. Bull. 24 3 1998 325 341
36. R.D. Reddy, M.S. Keshavan, and J.K. Yao Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline Schizophr. Bull. 30 4 2004 901 911
37. S.R. Ribeiz, D.P. Bassitt, J.A. Arrais, R. Avila, D.C. Steffens, and C.M. Bottino Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature CNS Drugs 4 2010 303 317 10.2165/11530260-000000000-00000
38. K.R. Rodvelt, G.R. Kracke, T.R. Schachtman, and D.K. Miller Ketamine induces hyperactivity in rats and hypersensitivity to nicotine in rat striatal slices Pharmacol. Biochem. Behav. 91 1 Nov 2008 71 76 10.1016/j.pbb.2008.06.012
39. P.D. Skosnik, and J.K. Yao From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot. Essent. Fat. Acids 69 6 2003 367 384 10.1016/j.plefa.2003.08.008
40. M. Tomiya, T. Fukushima, J. Kawai, C. Aoyama, S. Mitsuhashi, T. Santa, K. Imai, and T. Toyo'oka Alterations of plasma and cerebrospinal fluid glutamate levels in rats treated with the N-methyl-d-aspartate receptor antagonist, ketamine Biomed. Chromatogr. 20 6-7 2006 628 633 10.1002/bmc.677
41. B. Voss, R. Thienel, S. Leucht, and T. Kircher Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview Nervenarzt 79 1 2008 47 48 (50-2, 54-59)
42. J.K. Yao, C.G. Sistilli, and D.P. van Kammen Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia Prostaglandins Leukot. Essent. Fat. Acids 69 6 2003 429 436 10.1016/j.plefa.2003.08.015
43. A.J. Yu, and P. Dayan Acetylcholine in cortical inference Neural Netw. 15 4-6 2002 719 730
44. W. Zhang, M. Yamada, J. Gomeza, A.S. Basile, and J. Wess Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice J. Neurosci. 22 15 2002 6347 6352
45. L. Zimmer, S. Delion-Vancassel, G. Durand, D. Guilloteau, S. Bodard, J.C. Besnard, and S. Chalon Modifications of dopamine neurotransmission in the nucleus accumbens of rats deficient in n - 3 polyunsaturated fatty acids J. Lipid Res. 41 2000 32 40
46. A.I. Zugno, R.F. Julião, J. Budni, A.M. Volpato, D.B. Fraga, F.D. Pacheco, P.F. Deroza, R.D. Luca, M.B. de Oliveira, A.S. Heylmann, and J. Quevedo Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia Metab. Brain Dis. 28 3 2013 501 508 10.1007/s11011-013-9417-z